ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Department of Health and Human Services has awarded $12.3 million to the synthetic biology firm Amyris to develop domestic manufacturing for three small-molecule drugs on the Food and Drug Administration’s drug shortage list. Over the next 2 years, the firm will work with HHS to select and advance targets on the basis of Amyris’s technical capabilities. The award is part of a push from the Joe Biden Administration to deploy federal funds toward shoring up the domestic supply chain for chemicals, especially via biomanufacturing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter